Pharmaceutical composition for homeostasis stabilization and arresting pathological process in body

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition used for stabilization of homeostasis and arresting pathological processes in the body. Invention proposes a pharmaceutical composition as powder with particles size from 250 to 400 mcm comprising the following components by the first variant, wt.-%: carbon, 10.01-53.02; oxygen, 30.10-53.10; potassium, 0.26-1.99, and calcium, 0.20-31.37, and comprising the following components by the second variant, wt.-%: calcium, 0.35-31.20; carbon, 10.99-50.21; oxygen, 34.55-51.03; sulfur, 0.73-14.81, and phosphorus, 0.08-3.30. Invention provides compensation of trace elements unbalance that causes and accompanies many diseases, possibility for stabilization of trace element homeostasis and arresting pathological processes of different etiology.

EFFECT: improved and valuable medicinal properties of composition.

12 cl, 13 ex

 

The invention relates to pharmaceutical compositions for the stabilization of hemostasis and edema of pathological processes in the body, which will find use in the treatment of cardiovascular diseases, diseases of the gastrointestinal tract, diabetes, pathologies of musculoskeletal system, gynecological diseases, bronchial asthma, fatigue and some cancers.

Minerals play a significant role in creating the internal environment of the body with constant physico-chemical properties that guarantee the existence and normal functioning of cells. Change the content of mineral substances is either a response of the organism to developing pathology or due to depletion and the lack of mineral content in the main depot and insufficient intake outside. In many diseases diagnosed change the content of some mineral substances in biological fluids.

Currently, there are many selections on the basis of trace elements and/or mineral elements that offer on the market of medications as therapeutic, dietary or dermocosmetology drugs.

Known therapeutic composition Calcium D 3Nycomed" (firm AC Nycomed, Norway), containing 1250 mg calcium carbonate (equivalent to 500 mg calcium), 200 IU of cholecalciferol (vitamin D), 200 mg of sorbitol, 62 mg isomaltase, of 36.4 mg of povidone, 6 mg of magnesium stearate. This composition affects metabolic processes as a regulator of calcium and phosphorus in the body, reduces resorbtive and increase bone density. The composition is intended for the treatment of osteoporosis, and deficiency of calcium in the body.

Known therapeutic composition comprising a physiologically acceptable excipient and as active ingredients at least two minerals:

And - titanium oxide, providing protective and thixotropic functions, taken in the form of a suspension, and

B - antialgae tool, selected among caso3, MgO, Al2O3, Al(OH)3, MgCO3VASO3phosphate of aluminium, with a weight ratio of A:In=(1:10)-(10:1) and the content of the component, more than or equal to 5% weight of the composition (EP 0062578 A1, MCI And 61 To 33/10, publ. 13.10.82).

This song comes in the form of tablets, capsules, aqueous suspension gel for oral or rectal administration. This composition is recommended for the normalization of digestion in the treatment and prevention of acute gastritis, inflammation of the esophagus, dvenadcatiperstnoj the intestine, colitis, and other diseases of the digestive system and is effective in diabetes and various diets.

While known compositions are not able to compensate for the frequently observed imbalance of trace elements, which causes and accompanies many diseases of man. As you know, at deficiency, excess or imbalance of essential trace elements in the human body is disturbed microelementary homeostasis and develop pathological processes of various kinds. In addition, in the known compositions, as a rule, not considered synergistic and antagonistically aspect of interaction present elements.

The basis of the claimed invention is the task through a combination of mineral substances, having a synergistic interaction, to create a pharmaceutical composition on the basis of mineral substances, which will help stabilize microelementary homeostasis and arrest the pathological processes of various kinds.

This problem is solved by the creation of a pharmaceutical composition containing calcium, carbon, oxygen and potassium and is made in the form of a powder with a particle size of from 250 to 400 microns, with the following composition, wt.%: carbon 10,01-53,02; oxygen 30,10-53,10; potassium 0,26-1,99; calcium 0,20-31,37.

Thanks to the invention it has become possible to stabilize microelementary Goma is stasis, nausea pathological processes of various kinds.

An embodiment of the invention is that the pharmaceutical composition additionally contains sodium, magnesium, silicon, sulfur, phosphorus and chlorine, with the following composition, wt.%:

carbon 10,01, oxygen 50,22, potassium 0,45, calcium 31,37, sodium 0,57, magnesium 2,91, silicon 0,44, sulfur 0,65, phosphorus 3,07, chlorine 0,31, and can be recommended when the acidity of the stomach.

According to the invention suitable for the pharmaceutical composition additionally contains sodium, magnesium, aluminum, silicon, iron, phosphorus, chlorine, zinc, arsenic, silver, had the following composition, wt.%: carbon 45,65, oxygen 48,35, potassium 0,35, calcium 0,68, sodium 0,28, magnesium 0,19, aluminum 0,07, silicon 0,40, iron 1.97, phosphorus 0,23, chlorine 0,23, zinc 0,45, arsenic 0,42, silver 0,73. Such pharmaceutical composition may be used for lesions of the musculoskeletal system.

According to the invention suitable for the pharmaceutical composition additionally contains sodium, magnesium, aluminum, silicon, sulfur, iron, phosphorus and chlorine, when it had the following composition, wt.%: carbon 47,04-47,90, oxygen 45,74-48,98, potassium 1,19-0,43, calcium 0,30-0,99, sodium 0,07-0,18, magnesium 0,18-0,26, aluminum 0,07-0,12, silicon 1,58-3,20, sulfur 0,11-0,17, iron 0.08 to 0.42 and phosphorus 0,21-0,34, chlorine 0,08-0,35. Such pharmaceutical composition can be used for inflammation, skin irritation, p. and sleep disorders, General weakness.

According to the invention suitable for the pharmaceutical composition additionally contains sodium, aluminum, silicon, sulfur, iron, phosphorus and chlorine, when it had the following composition, wt.%: carbon 53,02, oxygen 30,10, potassium 0,68, calcium 0,26, sodium with 4.64, aluminum 0,20, silicon 0,57, sulfur 0,18, iron 0,21, phosphorus 0,12, chlorine 10,02. Such pharmaceutical composition may be recommended for osteoporosis.

According to the invention suitable for the pharmaceutical composition additionally contains sodium, magnesium, aluminum, silicon, iron, phosphorus, chlorine, zinc, arsenic, had the following composition, wt.%: carbon 46,25, oxygen 48,45, potassium 0,34, calcium 0,68, sodium 0,28, magnesium 0,18, aluminum 0,07, silicon 0,41, iron 1,99, phosphorus 0,23, chlorine 0,24, zinc 0,45, arsenic 0,43. Such pharmaceutical composition can be used in human blood.

According to the invention suitable for the pharmaceutical composition additionally contains silicon and chlorine, when it had the following composition, wt.%: carbon 47,31, oxygen 51,11, potassium 0,86, calcium 0,20, silicon 0,17, chlorine 0,35. Such pharmaceutical composition can be used for susceptibility to neoplasms.

According to the invention suitable for the pharmaceutical composition additionally contains sodium, magnesium, aluminum, silicon, sulfur, titanium, VC is the AOR, chlorine, when it had the following composition, wt.%: carbon 13,28, oxygen 53,10, potassium 1,99, calcium 12,36, sodium 0,55, magnesium 1,11, aluminum 3,49, silicon 10,50, sulfur 0.25 titanium 0,18, iron 2,33, chlorine 0,86. Such pharmaceutical composition can be used for physical growth retardation in children.

According to the invention suitable for the pharmaceutical composition additionally contains sodium, magnesium, silicon, titanium, iron, phosphorus, chlorine, manganese, boron, chromium, had the following composition, wt.%: carbon 47,14, oxygen 43,14, potassium 0,26, calcium 0,23, sodium 0,12, magnesium 0,12, silicon 7,58, titanium 0,68, iron 0,21, phosphorus 0,24, chlorine 0,10, manganese of 0.02, sulfur 0,11, chromium is 0.05. Such pharmaceutical composition can be recommended as with increased content of sugar in the blood and activate the body's immune system.

This task is also solved with the creation of a pharmaceutical composition, which contains calcium, carbon and oxygen, sulfur and phosphorus, in the form of powder with a particle size of from 250 to 400 microns, with the following composition, wt.%: calcium 0,35-31,20, carbon 10,99-50,21, oxygen 34,55-51,03, sulfur 0,73-14,81, phosphorus 0,08-3,30.

Thanks to the invention it has become possible to stabilize microelementary homeostasis and arrest the pathological processes of various kinds.

According to the invention suitable for the pharmaceutical composition to omnitele contained sodium, magnesium, iron, chlorine and manganese, when it had the following composition, wt.%: carbon 10,99, oxygen 51,03, calcium 31,20, sulfur 0,73, phosphorus 3,30, sodium 0,33, magnesium 1,96, iron 0,09, chlorine 0,34, manganese 0,03. Such pharmaceutical composition can be used at elevated physical and psycho-emotional stress.

Other objectives and advantages of the invention will become apparent from the subsequent detailed description of pharmaceutical compositions for the stabilization of hemostasis and edema of pathological processes in the body and examples of how to perform this pharmaceutical compositions.

It is known that of the 92 naturally occurring chemical elements 81 found in the human body. Only some items can be attributed to biogenic elements, chemical elements, constantly forming part of the body and plays a specific biological role.

To biogenic chemical elements are oxygen, carbon, hydrogen, nitrogen, calcium, phosphorus, potassium, sulfur, chlorine, sodium, magnesium, iron, zinc, copper, iodine, fluorine, manganese, molybdenum, cobalt, vanadium and selenium.

Calcium and phosphorus are the primary osteo-elements.

The sodium. Symptoms of hyponatremia are manifested by disorders of the Central nervous system - apathy, lack of exercise, hypotension, loss of appetite, muscle weakness, possible R is sweetie psychosis. As a result of decrease of basal vascular tone decreases HELL and developed tachycardia, possible violation of renal excretory function.

Aluminum contributes to the development and regeneration of epithelial, connective and bone tissue; the effect on the activity of digestive glands and enzymes.

Iron is involved in the breath, blood, immune and redox reactions; metabolic develop iron deficiency anemia, hemosiderosis, hemochromatosis, hemolytic α-, dis - and gipoplasticheskaya anemia.

Manganese affects the development of the skeleton, is involved in immune reactions, blood and tissue respiration; the lack of manganese celebrate depletion, delay synthesis glycosaminoglycans cartilage, growth retardation, and skeletal development.

Zinc is involved in hematopoiesis, in the activity of the endocrine glands; when zinc deficiency decreases the activity of carbonic anhydrase and, consequently, impaired excretory function of the kidney, see behind the growth.

The magnesium. If hypomagnesemia (lowering the concentration of magnesium below 1.4 mEq/l) see convulsions, which are heavier than hypocalcemia; in less severe cases of hypomagnesemia leads to the motor excitation, athetoid movements, psychosis marked which have the appearance of trophic ulcers on the skin, the deterioration in the digestion of food, additionally, when gipomagniemii celebrate phenomena are similar to manifestations of hypocalcemia, but what happens when normal levels of calcium in the blood.

Essential trace elements present in the human body in very small trace amounts, mostly referred to as 15 elements, namely Fe, J, Cu, Zn, Co, Cr, Mo, Ni, V, Se, Mn, As, F, Si, Li and b and Br.

Often the trace elements are part of the mineralized tissues of the skeleton, in other cases, the trace elements affect the organs and functions that are not related to the place of their deposition in the body.

At deficiency, excess or imbalance of essential trace elements in the human body is disturbed microelementary homeostasis and develop pathological processes of various kinds.

Studies have shown that loss of appetite is a symptom of deficiency or increased demand of zinc and iron; liver diseases are often associated with a deficiency or an increased need of the organism in selenium and zinc; the acidity of the stomach and bile stasis are a symptom of a deficiency or increased demand of magnesium; the defeat of the mucous membrane of the gastrointestinal tract is a symptom of deficiency or increased demand of the body in selenium, zinc, potassium, iron; constipation are what I symptom or deficit increased demand of magnesium, manganese, zinc and chromium; at dysbacteriosis detect the deficiency or increased need for zinc, iron, calcium, cobalt; at deficiency or increased demand of zinc, selenium, manganese, magnesium and calcium see symptoms of food Allergy; indigestion is a symptom of deficiency or increased demand of the body in chromium, zinc, iron; alcohol and drug abuse see the deficit or increasing the body's need for zinc, magnesium, selenium and lithium; poor memory is a symptom of deficiency or increased demand of zinc, manganese, copper; chronic fatigue see the deficit or increasing the body's need for magnesium and manganese; a state of General weakness, usually accompanied by a deficit or increased body's need for potassium, magnesium and zinc; sleep disorder see the deficit or increasing the body's need for magnesium and manganese; delays in mental development in children, as a rule, is accompanied by a deficiency or an increased need of the organism in manganese, zinc, copper, cobalt; the lag in physical development in children, usually accompanied by a deficit or increased need for zinc, copper, magnesium, cobalt, calcium and iron; hearing loss is a symptom of deficit is and or increased needs of the body of manganese and copper; impaired visual acuity is a symptom of deficiency or increased demand of zinc, copper, magnesium, chromium; if overweight, as a rule, see the deficit or increasing the body's need for chromium, manganese and zinc; increased blood sugar levels is accompanied by a deficit in the body and an increased need for chromium, manganese, zinc and magnesium, in violation of cardiovascular activity see the deficit or increasing the body's need for potassium, magnesium, and selenium; deficiency of copper, silicon and manganese detect pathology ligaments and joints; the fragility of bone tissue is a symptom of deficiency or increased demand of the body in manganese, calcium, magnesium, copper, silicon; anemia is a symptom of deficiency of iron, manganese, silver, titanium, zinc; hair see deficiency of zinc, selenium and silicon; poor growth of hair and nails observe deficiency of zinc, selenium, magnesium and silicon; the appearance of acne is a symptom of deficiency or increased demand of the body in chromium, selenium and zinc; inflammation, skin irritation is accompanied by a deficiency of zinc, selenium and silicon; depigmentation of the skin see a deficiency in the body copper, manganese and selenium; brittle nails is a symptom on the lack of or increased demand of the body in silicon and selenium; skin allergies are accompanied by a deficiency or an increased need for selenium and zinc; for allergies of the upper respiratory tract see deficiency of copper, manganese, selenium, calcium and cobalt; reduced immunity is accompanied by a deficiency of zinc, selenium, magnesium and cobalt; in pregnancy see increased demand of calcium, zinc, copper, iron and magnesium; disorders of the prostate gland accompanied by deficiency of zinc and selenium; violations in the gynecological field accompanied by a deficiency of copper, potassium and manganese; the propensity for kidney stone disease is a symptom of a deficiency or increased demand of the body in potassium, magnesium and zinc; at elevated physical and psycho-emotional stress see increased body's need for iron, zinc, chromium, potassium and manganese; anxiety in children are accompanied by a deficiency of magnesium and zinc; for susceptibility to neoplasms observed deficiency or increased need for zinc, selenium, manganese and silicon; the menopause in a woman's body see the deficiency of copper, selenium, magnesium and manganese; inflammatory diseases of the mouth is a symptom of deficiency or increased demand of zinc and copper.

The result mn is years of research and experiments by the author developed the pharmaceutical composition on the basis of mineral substances of natural origin, which in its first basic variant contains, wt%: carbon 10,01-53,02; oxygen 30,10-53,10; potassium 0,26-1,99; calcium 0,20-31,37.

The inventive pharmaceutical composition is in the form of powder with a particle size of from 250 to 400 microns.

Studies have confirmed that with the invention it has become possible to stabilize microelementary homeostasis and arrest the pathological processes of various kinds.

According to the invention the pharmaceutical composition, which in addition to the basic variant contains sodium, magnesium, silicon, sulfur, phosphorus and chlorine, thus has the following composition, wt.%: carbon 10,01, oxygen 50,22, potassium 0,45, calcium 31,37, sodium 0,57, magnesium 2,91, silicon 0,44, sulfur 0,65, phosphorus 3,07, chlorine 0,31. Such pharmaceutical composition can be used when the acidity of the stomach.

According to the invention the pharmaceutical composition, which in addition to the basic variant contains sodium, magnesium, aluminum, silicon, iron, phosphorus, chlorine, zinc, arsenic, silver, thus has the following composition, wt.%: carbon 45,65, oxygen 48,35, potassium 0,35, calcium 0,68, sodium 0,28, magnesium 0,19, aluminum 0,07, silicon 0,40, iron 1.97, phosphorus 0,23, chlorine 0,23, zinc 0,45, arsenic 0,42, silver 0,73. Such pharmaceutical composition may be used for lesions of the musculoskeletal system.

According to izaberete the Oia developed pharmaceutical composition, which in addition to the basic variant contains sodium, magnesium, aluminum, silicon, sulfur, iron, phosphorus and chlorine, thus has the following composition, wt.%: carbon 47,04-47,90, oxygen 45,74-48,98, potassium 0,43-1,19, calcium 0,30-0,99, sodium 0,07-0,18, magnesium 0,18-0,26, aluminum 0,07-0,12, silicon 1,58-3,20, sulfur 0,11-0,17, iron 0.08 to 0.42 and phosphorus 0,21-0,34, chlorine 0,08-0,35. Such pharmaceutical composition can be used for inflammation, skin irritation, sleep disorders, General weakness.

According to the invention the pharmaceutical composition, which in addition to the basic variant contains sodium, aluminum, silicon, sulfur, iron, phosphorus and chlorine, thus has the following composition, wt.%: carbon 53,02, oxygen 30,10, potassium 0,68, calcium 0,26, sodium with 4.64, aluminum 0,20, silicon 0,57, sulfur 0,18, iron 0,21, phosphorus 0,12, chlorine 10,02. Such pharmaceutical composition can be used for osteoporosis.

According to the invention the pharmaceutical composition, which in addition to the basic variant contains sodium, magnesium, aluminum, silicon, iron, phosphorus, chlorine, zinc, arsenic, thus has the following composition, wt.%: carbon 46,25, oxygen 48,45, potassium 0,34, calcium 0,68, sodium 0,28, magnesium 0,18, aluminum 0,07, silicon 0,41, iron 1,99, phosphorus 0,23, chlorine 0,24, zinc 0,45, arsenic 0,43. Such pharmaceutical composition can be used in n the violations blood.

According to the invention the pharmaceutical composition, which in addition to the basic variant contains silicon and chlorine, thus has the following composition, wt.%: carbon 47,31, oxygen 51,11, potassium 0,86, calcium 0,20, silicon 0,17, chlorine 0,35. Such pharmaceutical composition can be used for susceptibility to neoplasms.

According to the invention the pharmaceutical composition, which in addition to the basic variant contains sodium, magnesium, aluminum, silicon, sulfur, titanium, iron, chlorine, thus has the following composition, wt.%: carbon 13,28, oxygen 53,10, potassium 1,99, calcium 12,36, sodium 0,55, magnesium 1,11, aluminum 3,49, silicon 10,50, sulfur 0.25 titanium 0,18, iron 2,33, chlorine 0,86. Such pharmaceutical composition can be used for physical growth retardation in children.

According to the invention the pharmaceutical composition, which in addition to the basic variant contains sodium, magnesium, silicon, titanium, iron, phosphorus, chlorine, manganese, boron, chromium, it has the following composition, wt.%: carbon 47,14, oxygen 43,14, potassium 0,26, calcium 0,23, sodium 0,12, magnesium 0,12, silicon 7,58, titanium 0,68, iron 0,21, phosphorus 0,24, chlorine 0,10, manganese 0,02, boron 0,11, chromium is 0.05. Such pharmaceutical composition can be used with increased content of sugar in the blood and activate the body's immune system.

Also the author has developed the pharmaceutical composition on the basis of mineral substances, which in its second basic variant contains a carbon number 10,99-50,21 wt.%, the oxygen in the number 34,55-51,03 wt.%, calcium in the amount of 0.35-31,20 wt.%, sulfur in the number 0,73-14,81 wt.%, phosphorus in the amount of 0.08-3,30 wt.%.

The inventive pharmaceutical composition in the form of powder with a particle size of from 250 to 400 microns.

According to the invention the pharmaceutical composition, which advanced to the second basic variant contains sodium, magnesium, iron, chlorine and manganese, it has the following composition, wt.%: carbon 10,99, oxygen 51,03, calcium 31,20, sulfur 0,73, phosphorus 3,30, sodium 0,33, magnesium 1,96, iron 0,09, chlorine 0,34, manganese 0,03. Such pharmaceutical composition can be used under high emotional stress.

During the development of the claimed pharmaceutical compositions, the author has taken into account that in order to maintain homeostasis and the construction of the body, regardless of changing external conditions possible active and selective use of elements of the external environment.

Given that minerals are the most important catalysts of biochemical processes and metabolism, they play a significant role in the adaptation of the human organism in norm and pathology, the micro is a separate estimate possess a wide spectrum of synergistic and antagonistic relationships, namely between 15 known essential elements there are 105 bilateral and 455 tripartite interactions. If the minerals enter the body in quantities greater than biotic, that is physiologically necessary for the body, they can have an effect on those systems and functions that are affected in vivo.

According to the claimed invention in the proposed pharmaceutical composition is considered as synergistic and antagonistic aspect of interaction present elements and developed the optimal composition, in which specially selected dosage complementary active components provides a more effective action of the composition.

According to the claimed invention in the proposed pharmaceutical composition, the content of the elements is in the proportions and doses appropriate to the needs of the human body, providing good portability.

Sustainable preventive and therapeutic effect achieved with the acceptance of the claimed composition for at least three months.

The inventive composition at a dose of not more than 0.1 mg/day is recommended for reception in the morning on an empty stomach combined with 10 grams of butter 200 grams of melted milk cow.

Increased therapeutic effect is achieved when the Oceania the claimed pharmaceutical compositions with diet, aimed at cleansing the body and creating conditions for the assimilation of the ingredients of the composition of the walls of the stomach.

The inventive composition reduces the number of used sick of drugs for cardiovascular diseases, diseases of the gastrointestinal tract, diabetes, pathologies of musculoskeletal system, gynecological diseases, bronchial asthma, asthenia, some cancer. In some cases, patients refuse from the use of drugs.

The inventive pharmaceutical composition was studied in experiments on animals and in the clinic for the people.

For experimental confirmation of the positive effect of the inventive pharmaceutical composition on metabolic processes were tested on 40 outbred rats (males) weighing 150-200 grams with signs of mineral metabolism, divided into two groups.

The first group of white rats within 150 days received the claimed pharmaceutical composition in doses 0,00125 mg/kg of body weight. The second group served as control and did not receive the claimed pharmaceutical composition.

Before the experiment and after 30 days, animals were subjected to complete clinical examination. Blood and serum were determined by the number of Erie is Rozinov, leukocytes, hemoglobin, erythrocyte sedimentation rate, total protein content, hexoses, hydroxyproline, ionized and total calcium, inorganic phosphorus, magnesium, potassium, sodium, zinc, copper, iron, Nickel, glucose and the activity of Alp. The results show the positive influence of the pharmaceutical composition on the General condition of the experimental animals. Clinical studies conducted within 60 days after the beginning of the experiment with the experimental group of animals with clinical signs of disorders of mineral metabolism, failed to reveal any signs of mineral deficiencies. The control group of animals was noted signs of mineral deficiencies.

Morphological analysis of blood of experimental animals shows the positive effect of pharmacological compositions on haematopoiesis.

The number of erythrocytes increased from 4.7±0.12 to 6,85±0.4 million/µl, leukocytes from 8,16±0,41 to 19.4±0,24 thousand/ál. Biochemical blood analysis indicated a decrease in the concentration of hexoses and hydroxyproline, respectively, 1.5-3.0 times and 2.5-3.0 times that is the result of the normalization of the disturbed mineral metabolism. Normalization of metabolic processes in the body also indicates an increase in the activity of ionized calcium in 2 RA is a; inorganic phosphorus in 1.5 times; potassium 1.5 times; iron 2.4 times; zinc 1.8 times; copper in 2 times in comparison with the original data. Animals of the control group, all these indicators have not been changed.

Prolonged use of the claimed composition had a stimulating effect on the processes of biosynthesis of glycosaminoglycan, collagen, bone, cartilage, loose connective tissue and collagenolysis function of fibroblasts in the wall of blood vessels.

A beneficial effect of the claimed composition due to its high sorption properties, facilitate decontamination in the gastrointestinal tract of various toxins, normalize metabolism and improve digestion. This increases the body's resistance to various diseases.

Clinical study of the claimed pharmaceutical compositions performed on the volunteers.

Evaluating the overall health of the volunteers, their vessels and organs was performed according to Voll in arbitrary units (50 used).

Overall health volunteer without the use of the claimed composition - 37.

Overall health volunteer when using the claimed composition - 49.

The state of the cerebral vessels of volunteer without the use of the claimed composition - 32.

<> The state of the cerebral vessels of volunteer when using the claimed composition - 42.

The condition of the eyes of a volunteer without the use of the claimed composition - 28.

The condition of the eyes of a volunteer when using the claimed composition - 40.

The state of breast cancer volunteer without the use of the claimed composition - 30.

The state of breast cancer volunteer when using the claimed composition - 40.

The condition of the vessels of the heart without the use of the claimed composition - 36.

The condition of the vessels of the heart when using the claimed composition - 45.

The inventive pharmaceutical composition can compensate for the imbalance of essential trace elements in the human body and initially has a preventive effect can reduce the incidence of influenza, colds, bronchitis, pneumonia, and bacterial infections of the gastrointestinal tract and other infections, subsequent reception of the inventive composition provides a complex effect on the body, in particular normalizes the endocrine system, including lipid metabolism, promotes the resorption in the body cholesterol deposits on the walls of blood vessels, strengthens the coronary artery. Thanks to the restoration work of the cardiovascular system the blood is enriched with carbon, oxygen, calcium, the other minerals, it has an effective influence on skin, hair, nails, thyroid gland, helps to treat diabetes, diathesis, allergies, obesity, pancreatitis, psoriasis, scoliosis, degenerative disc disease, infertility, reduced sexual potency in men, impaired growth and development of children, hemorrhoids, adenoma, joints and intervertebral discs. In cancer of the inventive composition effectively restores the cellular metabolism of the body. The inventive composition allows to eliminate chronic fatigue syndrome, restore the function of the liver, gastrointestinal tract, pancreas, brain and Central nervous system.

The following examples are given to illustrate the invention and are in no way limiting as the scope of protection of the pharmaceutical composition, and the range of effectiveness of each specific version.

Example 1

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 400 μm, contains a carbon number 47,17 wt.%, the oxygen in the number 52,23 wt.%, potassium in an amount of 0.44 wt.%, calcium in the amount of 0.16 wt.%.

Specified pharmaceutical composition may be recommended to stabilize hemostasis and edema of pathological processes in the body.

Example 2

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 40 μm and contains, wt.%: carbon 10,01, oxygen 50,22, potassium 0,45, calcium 31,37, sodium 0,57, magnesium 2,91, silicon 0,44, sulfur 0,65, phosphorus 3,07, chlorine 0,31.

Mentioned pharmaceutical composition can be recommended to patients suffering from high acidity of the stomach.

Example 3

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 400 microns and contains, wt%: carbon 45,65, oxygen 48,35, potassium 0,35, calcium 0,68, sodium 0,28, magnesium 0,19, aluminum 0,07, silicon 0,40, iron 1.97, phosphorus 0,23, chlorine 0,23, zinc 0,45, arsenic 0,42, silver 0,73.

Mentioned pharmaceutical composition can be recommended to patients suffering from lesions of the musculoskeletal system.

Example 4

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 400 microns and contains, wt%: carbon 47,04-47,90, oxygen 45,74-48,98, potassium 0,43-1,19, calcium 0,30-0,99, sodium 0,07-0,18, magnesium 0,18-0,26, aluminum 0,07-0,12, silicon 1,58-3,20, sulfur 0,11-0,17, iron 0.08 to 0.42 and phosphorus 0,21-0,34, chlorine 0,08-0,35.

Mentioned pharmaceutical composition can be recommended to patients suffering from inflammation, irritation of the skin.

Example 5

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 400 microns and contains, wt%: carbon 53,02, oxygen 30,10, potassium 0,68, calcium 0,26, sodium with 4.64, aluminum 0,20, silicon 0,57, sulfur 0,18, iron 0,21, phosphorus 0,12, chlorine 10,02.

Specified pharmaceutical HDMI is tion can be recommended to patients, suffering from osteoporosis.

Example 6

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 400 microns and contains, wt%: carbon 46,25, oxygen 48,45, potassium 0,34, calcium 0,68, sodium 0,28, magnesium 0,18, aluminum 0,07, silicon 0,41, iron 1,99, phosphorus 0,23, chlorine 0,24, zinc 0,45, arsenic 0,43.

Mentioned pharmaceutical composition can be recommended to patients see human blood.

Example 7

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 400 microns and contains, wt%: carbon 47,31, oxygen 51,11, potassium 0,86, calcium 0,20, silicon 0,17, chlorine 0,35.

Specified pharmaceutical composition may be recommended for patients with a predisposition to neoplasms.

Example 8

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 400 microns and contains, wt%: carbon 13,28, oxygen 53,10, potassium 1,99, calcium 12,36, sodium 0,55, magnesium 1,11, aluminum 3,49, silicon 10,50, sulfur 0.25 titanium 0,18, iron 2,33, chlorine 0,86.

Mentioned pharmaceutical composition can be recommended for children with retarded physical development.

Example 9

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 400 microns and contains, wt%: carbon 47,14, oxygen 43,14, potassium 0,26, calcium 0,23, sodium 0,12, magnesium 0,12, silicon 7,58, titanium 0,68, iron 0,21, phosphorus 0,24, chlorine 0,10, manganese 0,02, boron 0,11, chrome 0,05.

Specified pharmaceutical composition may be recommended for patients with blood high sugar content and to activate the body's immune system.

Example 10

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 400 microns and contains, wt%: calcium 0,35-31,20, carbon 10,99-50,21, oxygen 34,55-51,03, sulfur 0,73-14,81, phosphorus 0,08-3,30.

Specified pharmaceutical composition may be recommended to stabilize hemostasis and edema of pathological processes in the body.

Example 12

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 400 microns and contains, wt%: carbon 10,99, oxygen 51,03, calcium 31,20, sulfur 0,73, phosphorus 3,30, sodium 0,33, magnesium 1,96, iron 0,09, chlorine 0,34, manganese 0,03.

Specified pharmaceutical composition may be recommended at elevated physical and psycho-emotional stress.

Example 13

The pharmaceutical composition has the form of a powder with a particle size of from 250 to 400 μm and contains a carbon number 50,21 wt.%, the oxygen in the number 34,55 wt.%, calcium in the amount of 0.35 wt.%, sulfur in the amount of 14,81 wt.%, phosphorus in the amount of 0.08 wt.%.

Mentioned pharmaceutical composition can be recommended to patients suffering from diseases of the joints, ligaments.

1. Pharmaceutical composition for the stabilization of hemostasis and edema Pato is logicheskih processes in the body, characterized in that it contains calcium, carbon, oxygen and potassium, in the form of powder with a particle size of from 250 to 400 microns, with the following composition, wt.%:

Carbon10,01-53,02
Oxygen30,10-53,10
Potassium0,26-1,99
Calcium0,20-31,37

2. The pharmaceutical composition according to claim 1, which can be used when the acidity of the stomach and additionally contains sodium, magnesium, silicon, sulfur, phosphorus and chlorine, with the following composition, wt.%:

Carbon10,01
Oxygen50,22
Potassium0,45
Calcium31,37
Sodium0,57
Magnesium2,91
Silicon0,44
Sulfur0,65
Phosphorusof 3.07
Chlorine0,31

3. The pharmaceutical composition according to claim 1, which can be used for lesions of the musculoskeletal system and additionally contains sodium, magnesium, aluminum, silicon, iron, phosphorus, chlorine, zinc, arsenic, silver, with abuses composition, wt.%:

Carbon45,65
Oxygen48,35
Potassium0,35
Calcium0,68
Sodium0,28
Magnesium0,19
Aluminum0,07
Silicon0,40
Iron1,97
Phosphorus0,23
Chlorine0,23
Zinc0,45
Arsenic0,42
Silver0,73

4. The pharmaceutical composition according to claim 1, which can be used for inflammation, skin irritation, sleep disorders, General weakness, additionally contains sodium, magnesium, aluminum, silicon, sulfur, iron, phosphorus and chlorine, with the following composition, wt.%:

Carbon47,04-47,90
Oxygen45,74-48,98
Potassium0,43-1,19
Calcium0,30-0,99
Sodium0,07-0,18
Magnesium0,18-0,26
Aluminum0,07-0,12
Silicon1,58-3,20
Sulfur0,11-0,17
Iron0,08-0,42
Phosphorus0,21-0,34
Chlorine0,08-0,35

5. The pharmaceutical composition according to claim 1, which can be used for osteoporosis, additionally contains sodium, aluminum, silicon, sulfur, iron, phosphorus and chlorine, with the following composition, wt.%:

Carbon53,02
Oxygen30,10
Potassium0,68
Calcium0,26
Sodiumwith 4.64
Aluminum0,20
Silicon0,57
Sulfur0,18
Iron0,21
Phosphorus0,12
Chlorine10,02

6. The pharmaceutical composition according to claim 1, which can be used for human blood, additionally contains sodium, magnesium, aluminum, silicon, iron, phosphorus, chlorine, zinc, arsenic, with the following composition, wt.%:

Carbon46,25
Oxygen48,45
Potassium 0,34
Calcium0,68
Sodium0,28
Magnesium0,18
Aluminum0,07
Silicon0,41
Iron1,99
Phosphorus0,23
Chlorine0,24
Zinc0,45
Arsenic0,43

7. The pharmaceutical composition according to claim 1, which can be used for susceptibility to tumors, additionally contains silicon and chlorine, with the following composition, wt.%:

Carbon47,31
Oxygen51,11
Potassium0,86
Calcium0,20
Silicon0,17
Chlorine0,35

8. The pharmaceutical composition according to claim 1, which can be used for physical growth retardation in children, additionally contains sodium, magnesium, aluminum, silicon, sulfur, titanium, iron, chlorine, in the following composition, wt.%:

Carbon13,28
Oxygen53,10
Potassium 1,99
Calcium12,36
Sodium0,55
Magnesium1,11
Aluminum3,49
Silicon10,50
Sulfur0,25
Titanium0,18
Iron2,33
Chlorine0,86

9. The pharmaceutical composition according to claim 1, which can be used with increased content of sugar in the blood, additionally contains sodium, magnesium, silicon, titanium, iron, phosphorus, chlorine, manganese, boron, chromium, in the following composition, wt.%:

Carbon47,14
Oxygen43,14
Potassium0,26
Calcium0,23
Sodium0,12
Magnesium0,12
Silicon7,58
Titanium0,68
Iron0,21
Phosphorus0,24
Chlorine0,10
Manganese0,02
Bor0,11
Chrome0,05

10. The pharmaceutical composition according to claim 1, cat heaven can be used to activate the body's immune system, additionally contains sodium, magnesium, silicon, titanium, iron, phosphorus, chlorine, manganese, boron, chromium, in the following composition, wt.%:

Carbon47,14
Oxygen43,14
Potassium0,26
Calcium0,23
Sodium0,12
Magnesium0,12
Silicon7,58
Titanium0,68
Iron0,21
Phosphorus0,24
Chlorine0,10
Manganese0,02
Sulfur0,11
Chrome0,05

11. Pharmaceutical composition for the stabilization of hemostasis and edema of pathological processes in the body, characterized in that it contains calcium, carbon, oxygen, sulfur, phosphorus, in the form of powder with a particle size of from 250 to 400 microns, with the following composition, wt.%:

Calcium0,35-31,20
Carbon10,99-50,21
Oxygen34,55-51,03
Sulfur0,73-14,81
Phosphorus

12. The pharmaceutical composition according to claim 11, which can be used at elevated physical and psycho-emotional stress, additionally contains sodium, magnesium, iron, chlorine, and manganese, in the following composition, wt.%:

Carbon10,99
Oxygen51,03
Calcium31,20
Sulfur0,73
Phosphorus3,30
Sodium0,33
Magnesium1,96
Iron0,09
Chlorine0,34
Manganese0,03



 

Same patents:

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of 5-amidino-2-hydroxybenzenesulfonamide of the general formula (I): wherein R2 means hydrogen atom (H), lower alkyl that can comprise a substitute chosen from the group (A): wherein (A) means -COORA, -CONRBRC, 3-7-membered monocyclic heterocycloalkyl group comprising one or two heteroatom in ring chosen from atoms N, O, S that can comprise oxo-group and 5-6-membered monocyclic aromatic heterocyclic group comprising one-three heteroatoms in ring chosen from atoms N, O, S that can comprise oxo-group or lower alkyl wherein RA means hydrogen atom (H), 3-7-membered monocyclic aliphatic alkyl group, lower alkyl that can comprises a substitute chosen from the group (i) wherein (i) means -COORA1 wherein RA1 means hydrogen atom (H), -OCORA2 wherein RA2 means lower alkyl group, -OCOORA3 wherein RA3 means lower alkyl, -ORA4 wherein RA4 means hydrogen atom (H), lower alkyl -CONRA5RA6 wherein RA5 and RA6 mean independently hydrogen atom (H), lower alkyl, or -NRA5RA6 forms 5-6-membered monocyclic amino-group comprising one heteroatom in ring chosen from atoms N, O, S and another one distinct from nitrogen atom (N) instead a bond; wherein RB and RC mean independently hydrogen atom (H), lower alkyl that can comprise a substitute chosen from the group (ii), or -NRBRC forms 5-6-membered monocyclic amino-group comprising one heteroatom in ring chosen from atoms N, O, S and another one distinct from nitrogen atom (N) instead a bond; (ii) means -COORB1 wherein RB1 means hydrogen atom (H), lower alkyl; T means oxygen atom (O), sulfonyl group; or TR1 means -SO2NRB3RC3 wherein RB3 and RC3 means independently hydrogen atom (H), lower alkyl; R2 means lower alkyl, phenyl that can comprise one-three substitutes chosen from the group (B) wherein (B) means halogen atom, -COORE, sulfamoyl, lower alkylsulfonyl wherein RE means lower alkyl; Q means hydrogen atom (H), lower alkyl that can comprise a substitute chosen from the group (D) wherein (D) means 5-6-membered monocyclic aromatic heterocyclic group that can comprise one-three heteroatom chosen from atoms N, O, S that can comprise a substitute chosen from the group (iv) wherein (iv) means oxo-group, lower alkyl; Z means hydrogen atom (H), hydroxyl group (OH), -COORN wherein RN means lower alkyl that can comprise a substitute chosen from the group (viii) wherein (viii) means -OCOR5 wherein RN5 means lower alkyl that can comprise -OCORN51 wherein RN51 means lower alkyl; or its pharmaceutically acceptable salt. Compounds of the formula (I) inhibit activated factor X in blood coagulation system that allows their using in pharmaceutical composition. Also, invention describes intermediate compounds.

EFFECT: valuable medicinal properties of compounds and compositions.

12 cl, 5 tbl

FIELD: medicine, cardiology.

SUBSTANCE: invention proposes an agent for correction of abdominal complications in acute period in myocardium infarction. Proposed agent represents ondansetron or domperidone. Agent reduces frequency of hyperemia occurring, improved indices of intestine contractions, promotes to declining lethality in acute period in myocardium infarction.

EFFECT: improved and valuable medicinal properties of agent.

4 tbl, 6 dwg

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes a pharmaceutical preparation based on angiotensin-converting enzyme inhibitor, its using in prophylaxis of insult, diabetes and/or congestive cardiac insufficiency and corresponding methods for its using in patient with maintenance heart function and subjected for risk of cardiovascular attack due to previous history of ischemic disease, insult or peripheral arterial disease. In particular, inhibitor of angiotensin-converting enzyme can be chosen from ramipril, ramiprilat, lisinopril, enalapril and enalaprilat. Invention promotes to reducing the total lethality of patients group in case of cardiovascular diseases, cardiac attacks and insults, the necessity for carrying out procedures for revascularization (such as surgery operation for coronary shunt, angioplasty with using balloon and so on) and diabetic complication are diminished.

EFFECT: improved and valuable medicinal properties of preparations.

19 cl, 1 ex

FIELD: medicine, cardiology, endocrinology.

SUBSTANCE: method involves administration of amlodipine in the dose 5 mg, once in the same time and metformin in the dose 500 mg, 2 times per 24 h in patients at the background of individually selected hypocaloric diet. Treatment is carried out for 8 weeks, not less. Method provides optimization of intravascular activity of platelets due to correction of primary homeostasis and the level of their antioxidant protection. Invention can be used for rapid optimization of functions of platelets at metabolic syndrome.

EFFECT: improved and enhanced method for optimization.

2 ex

FIELD: medicine, cardiology, endocrinology.

SUBSTANCE: method involves administration of simvastatin in patients in the dose 5 mg, once before night, and nebivolol in the dose 5 mg, once in the same time on the background of individually selected hypocaloric diet. Treatment is carried out for 24 weeks, not less. Method provides optimization of intravascular activity of platelets due to normalization of lipid composition of their membranes and enhancing level of antioxidant protection. Invention can be used in correction of lipid activity of platelet membranes and activity at metabolic syndrome.

EFFECT: improved correction method.

2 ex

FIELD: medicine and biopharmacology.

SUBSTANCE: claimed biotransplant contains mesenchyme stem cells (MSC) obtained from fetal, donor or autologous material. Tissue is desagregated, obtained cell suspension is resuspended and cultivated on growth medium containing transferrin, insulin, fibroblast growth factor and heparin to accumulate mature stroma in cells. Method for treatment of lung hypertension includes intravenous drip-feeding of MSC in amount of 50-500 millions cells in 50-100 ml of physiological solution.

EFFECT: method for treatment of improved effectiveness having no undesired side effects.

6 cl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to using a pharmaceutical preparation comprising beta-blocking agent in the maintenance dose less 50 mg, in particular, in the range from 25 mg to 47 mg in mixture with a pharmaceutically acceptable adjuvant, vehicle or carrier. The preparation is used in treatment of atherosclerosis and diseases associated with thereof. Invention provides decreasing dose of the preparation.

EFFECT: improved using method.

6 cl, 3 tbl, 1 ex

FIELD: organic chemistry, biochemistry, pharmacy.

SUBSTANCE: invention relates to 5-aminoalkylpyrazolo[4,3-d]pyrimidines of the general formula (I): wherein R1 and R2 are similar or different and represent independently of one another (C1-C8)-alkyl group; R3 and R4 are similar or different and represent independently of one another (C1-C8)-alkoxy-group or halogen atom; R5 and R6 can be similar or different and represent independently of one another hydrogen atom, linear or branched (C1-C8)-alkyl group that can be substituted with one or more hydroxyl groups, (C1-C8)-alkoxy-, amino-, mono-(C1-C8)-alkyl-amino-, di-[(C1-C8)-alkyl]-amino-, N-morpholino- or pyridyl groups or in common with nitrogen atom to which they are bound form unsaturated heterocyclic ring that comprises optionally one or more additional atoms of nitrogen and/or oxygen and substituted with one or more hydroxyl, (C1-C8)-alkylol, (C1-C6)-oligohydroxyalkyl, amino-, mono-[(C1-C8)-alkyl]-amino- or di-[(C1-C8)-alkyl]-amino-groups. Proposed compounds inhibit activity of cGMP-phosphodiesterase and can be used in treatment of states of cardiovascular system and for treatment in potency disturbances. Also, invention relates to a medicinal preparation used for inhibition of activity of cGMP-phosphodiesterase based on indicated compounds, a method for preparing compounds of the formula (I) and a method for preparing the medicinal preparation.

EFFECT: improved preparing method, valuable medicinal and biochemical properties of compounds and composition.

7 cl, 15 ex

FIELD: medicine, experimental cardiopharmacology.

SUBSTANCE: in an experiment one should intragastrically introduce APP inhibitor analapryl for laboratory animal at endothelial dysfunction, at the background of its modeling, at the dosage of 0.5 mg/kg and intraperitoneally - L-arginine at the dosage of 200 mg/kg once daily. This enables to activate correction of endothelial dysfunction due to enhancing enzymatic NO formation, L-carnitine being its donator.

EFFECT: higher efficiency of correction.

1 ex, 2 tbl

FIELD: medicine, therapy.

SUBSTANCE: invention relates to a method for treatment of arterial hypertension. Method involves administration of one or some medicinal preparations in biorhythmical sequence taken among the following order: papaverin, common wormwood tincture - at 7.00 - 9.00 a. m.; thrombo-ACC, rheopro, clopidogrel - at 9.00 - 11.00 a. m.; No-Spa - at 11.00 a. m.; trental - at 11.15 a. m.; atenolol, propranolol, metoprolol, nifedipin, verapamil, cordaron, valerian, motherwort - at 11.30 a. m.; polyvitamins, fenules - at 1.00 p. m.; No-Spa - at 4.00 p. m.; trental - at 4.15 p. m.; hypothiazid, furosemid, verospiron, captopril, enalapril, prestarium, quinapril, ramipril, losartan, valsartan - at 4.30 p. m.; No-Spa - at 7.00 p. m.; trental - at 7.15 p. m.; atenolol, propranolol, metoprolol, nifedipin, verapamil, cardura, valerian, motherwort, phenazepam, coaxil, paxil - at 7.30 p. m.; ginseng - at 9.00 p. m.; Essentiale, simvastatin, lovastatin - at 11.00 p. m. Method provides recovery of levels synchronization in organization of organ-forming systems that allows carrying out the effect on the arterial pressure value in the corresponding time of day.

EFFECT: improved treatment method.

1 tbl, 2 dwg, 1 ex

Cannabinoid drugs // 2273476

FIELD: medicine.

SUBSTANCE: method involves administering tetrahydrocannabinol derivatives for inhibiting cell proliferation in mammalians.

EFFECT: enhanced effectiveness of treatment.

17 cl, 4 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: method involves administering Capecitabine during 14 days within 15 days long treatment course in everyday mode and Oxyplatin at a dose of 50 mg/m2 at the first, eighth and fifteenth treatment day. Pause between treatment courses is 2-3 weeks long.

EFFECT: enhanced effectiveness of treatment.

FIELD: medicine.

SUBSTANCE: method involves evaluating neurological status and crude protein and calcium level in cerebrospinal fluid after intrathecally introducing methotrexate in the amount of 5 mg in auto liquor in postoperative period before starting chemotherapy. 5 ml of liquor are taken in a day and methotrexate course dose is selected depending on neurological status and changes in crude protein and calcium level in cerebrospinal fluid in liquor. No changes in neurological status and crude protein and calcium level being observed, methotrexate dose is increased by 20% when compared to the test dose. No changes in neurological status and increased crude protein level by 100% or higher and reduced calcium level by a value between 20% and 40% being observed, methotrexate dose is reduced by 20% when compared to the test dose. Negative changes in neurological status and crude protein being increased more than by 200% and reduced calcium level by more than 40% and reduced crude protein and increased calcium content being observed, chemotherapy course is restricted to already introduced methotrexate test dose.

EFFECT: improved biochemical criteria.

1 tbl

FIELD: medicine, oncology.

SUBSTANCE: method involves autoblood sample taking off in the amount 200-250 ml into a sterile flask with hemopreserving agent "Glugitsir" followed by centrifugation at 1500 rev/min for 30 min. Then supernatant plasma is placed into another sterile flask with a hemopreserving agent and cellular precipitate is reinfused. A single dose of a cytostatic agent is mixed with 10-100 ml of autoplasma, incubated at temperature 37°C for 1 h and administrated through catheter in abdominal cavity by puncture in lower quadrant of abdomen. Procedure is repeated if necessary. Method provides decreasing toxicity of chemotherapy, simple method and uniform distribution of volume of injected preparation for all abdomen cavity. Invention can be used in carrying out chemotherapy of abdomen cavity tumors with ascites.

EFFECT: improved method for treatment.

1 ex

FIELD: medicine, oncology.

SUBSTANCE: invention relates to a method for treatment of malignant tumors. Method involves chemotherapy and hormonal therapy. Insulin of short action is administrated by subcutaneous injection in the dose 8-10 U as a hormone. In appearance of hypoglycemia symptoms chemopreparations are administrated in 200-250 ml of 40% glucose solution. Administration is carried out once time for 3-6 weeks by the known schedule. Method provides enhancing antitumor effect of chemopreparations due to reducing delivery of glucose into malignant cell, its energy deficiency and reducing adaptation ability to chemotherapy.

EFFECT: improved treatment method.

2 ex

FIELD: medicine, immunology, oncology.

SUBSTANCE: invention relates to development of a method and composition promoting to enhancing absorption of immunocytokines in tumors. Compositions are based on combination of cytokine with agent enhancing absorption of immunocytokine. Invention provides the enhanced effectiveness of therapy of tumors and metastasis in mammals.

EFFECT: improved and valuable medicinal method of treatment.

27 cl, 10 dwg, 11 ex

FIELD: medicine, oncology, dermatology.

SUBSTANCE: the present innovation deals with treating mammalians due to introducing nonpsychotropic compounds - tetrahydrocannabinol derivatives, adjulemic acid derivative, in particular. The innovation suggested enables to either decrease or prevent cell proliferation at the following diseases: psoriasis, tumors along with low toxicity level of therapy conducted.

EFFECT: higher efficiency.

11 cl, 4 dwg, 1 ex, 2 tbl

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention relates to crystalline polymorphic modifications of strong acting epotilone analog of forma A and forma B represented by the formula (I): Invention proposes a crystalline substance representing a mixture of form A and form B of epotilone analogs. Invention proposes two variants of a method for preparing crystalline polymorphic modification representing form A. Also, invention proposes a pharmaceutical composition inhibiting angiogenesis and comprising an active component that represents crystalline polymorphic modification of epotilone analog of form A, form B or a crystalline polymorphic modification of epotilone analog of the formula (I) wherein this modification has no amorphous component, and a pharmaceutically acceptable carrier. Also, invention proposes a method for treatment of cancer comprising administration in mammal the effective dose of crystalline polymorphic modification of epotilone analog. Invention provides preparing crystalline polymorphic modifications of strong acting epotilone analog of the formula (I) characterizing by improved properties for using in therapy of cancer species.

EFFECT: improved preparing methods, valuable medicinal properties of compounds and composition.

16 cl, 9 dwg, 7 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: method involves incubating antibiotics and/or chemopreparations in therapeutic doses with autoplasma 30 min at 37°C and introducing the preparations into paravaginal cellular tissue to patients suffering from genitalia diseases and into paravesical cellular tissue to patients suffering from urinary bladder diseases and into pararectal cellular tissue to patients suffering from rectum diseases. Tumor proliferation into neighboring small pelvis organs (into paravaginal and/or pararectal and/or paravesical cellular tissue) taking place, the treatment is applied twice a week.

EFFECT: increased pathological focus regression percent; reduced manifestations of drug therapy complications.

FIELD: medicine, in particular treatment of malignant neoplasm.

SUBSTANCE: claimed method includes administration of vaccine representing complex of heat shock protein and tumor peptide, isolated from subject tumor tissue, and radioactive preparation Oncofer. Oncofer is administered both during vaccination course and after vaccination.

EFFECT: stable antitumor immunity, enhanced tumor cell apoptosis and blocked blood supply due to alteration of erythrocyte properties in tumor caused by radioactive preparation and activation of clot formation in said vessels.

2 cl, 4 ex, 2 dwg

FIELD: chemistry of organophosphorus compounds, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new bisamidate phosphonate compounds that are inhibitors of fructose 1,6-bis-phosphatase. Invention describes a compound of the formula (IA): wherein compound of the formula (IA) is converted in vivo or in vitro to compound of the formula M-PO3H2 that is inhibitor of fructose 1,6-bis-phosphatase and wherein M represents R5-X- wherein R5 is chosen from a group consisting of compounds of the formula or wherein each G is chosen from the group consisting of atoms C, N, O, S and Se and wherein only one G can mean atom O, S or Se and at most one G represents atom N; each G' is chosen independently from the group consisting of atoms C and N and wherein two G' groups, not above, represent atom N; A is chosen from the group consisting of -H, -NR42, -CONR42, -CO2R3, halide, -S(O)R3, -SO2R3, alkyl, alkenyl, alkynyl, perhaloidalkyl, haloidalkyl, aryl, -CH2OH, -CH2NR42, -CH2CN, -CN, -C(S)NH2, -OR2, -SR2, -N3, -NHC(S)NR42, -NHAc, or absent; each B and D is chosen independently from the group consisting of -H, alkyl, alkenyl, alkynyl, aryl, alicyclyl, aralkyl, alkoxyalkyl, -C(O)R11, -C(O)SR11, -SO2R11, -S(O)R3, -CN, -NR92, -OR3, -SR3, perhaloidalkyl, halide, -NO2, or absent and all groups except for -H, -CN, perhaloidalkyl, -NO2 and halide are substituted optionally; E is chosen from the group consisting of -H, alkyl, alkenyl, alkynyl, aryl, alicyclyl, alkoxyalkyl, -C(O)OR3, -CONR42, -CN, -NR92, -NO2, -OR3, -SR3, perhaloidalkyl, halide, or absent; all groups except for -H, -CN, perhaloidalkyl and halide are substituted optionally; J is chosen from the group consisting of -H, or absent; X represents optionally substituted binding group that binds R5 with phosphorus atom through 2-4 atoms comprising 0-1 heteroatom chosen from atoms N, O and S with exception that if X represents urea or carbamate then there are 2 heteroatoms that determine the shortest distance between R5 and phosphorus atom and wherein atom bound with phosphorus means carbon atom and wherein X is chosen from the group consisting of -alkyl(hydroxy)-, -alkynyl-, - heteroaryl-, -carbonylalkyl-, -1,1-dihaloidalkyl-, -alkoxyalkyl-, -alkyloxy-, -alkylthioalkyl-, -alkylthio-, -alkylaminocarbonyl-, -alkylcarbonylamino-, -alkoxycarbonyl-, -carbonyloxyalkyl-, -alkoxycarbonylamino- and -alkylaminocarbonylamino- and all groups are substituted optionally; under condition that X is not substituted with -COOR2, -SO3H or -PO3R22; n means a whole number from 1 to 3; R2 is taken among the group -R3 and -H; R3 is chosen from the group consisting of alkyl, aryl, alicyclyc and aralkyl; each R4 is chosen independently from the group consisting of -H and alkyl, or R4 and R4 form cycloalkyl group; each R9 is chosen independently from the group consisting of -H, alkyl, aryl, aralkyl and alicyclyl, or R9 and R9 form in common cycloalkyl group; R11 is chosen from the group consisting of alkyl, aryl, -NR22 and -OR2; each R12 and R13 is chosen independently from the group consisting of hydrogen atom (H), lower alkyl, lower aryl, lower aralkyl wherein all groups are substituted optionally, or R12 and R13 in common are bound through 2-5 atoms comprising optionally 1-2 heteroatoms chosen from the group consisting of atoms O, N and S to form cyclic group; each R14 is chosen independently from the group consisting of -OR17, -N(R17)2, -NHR17, -NR2OR19 and -SR17; R15 is chosen from the group consisting of -H, lower alkyl, lower aryl, lower aralkyl, or in common with R16 is bound through 2-6 atoms comprising optionally 1 heteroatom chosen from the group consisting of atoms O, N and S; R16 is chosen from the group consisting of -(CR12R13)n-C(O)-R14, -H, lower alkyl, lower aryl, lower aralkyl, or in common with R15 is bound through 2-6 atoms comprising optionally 1 heteroatom chosen from the group consisting of atoms O, N and S; each R17 is chosen independently from the group consisting of lower alkyl, lower aryl and lower aralkyl and all groups are substituted optionally, or R17 and R17 at atom N are bound in common through 2-6 atoms comprising optionally 1 heteroatom chosen from the group consisting of atoms O, N and S; R18 is chosen independently among the group consisting of hydrogen atom (H), lower alkyl, aryl, aralkyl, or in common with R12 is bound through 1-4 carbon atoms forming cyclic group; each R19 is chosen independently from the group consisting of -H, lower alkyl, lower aryl, lower alicyclyl, lower aralkyl and -COR3; and under condition that when G' represents nitrogen atom (N) then the corresponding A, B, D or E are absent; at least one from A and B, or A, B, D and E is chosen from the group consisting of -H, or absent; when G represents nitrogen atom (N) then the corresponding A or B is not halide or group bound directly with G through a heteroatom; and its pharmaceutically acceptable salts. Also, invention describes a method for treatment or prophylaxis of diabetes mellitus, a method for inhibition of activity 0f fructose 1,6-bis-phosphatase, a method for decreasing blood glucose in animals, a method for treatment of diseases associated with glycogen deposition, a method for inhibition of gluconeogenesis in animal and a pharmaceutical composition based on compounds of the formula (IA).

EFFECT: valuable medicinal and biochemical properties of compounds.

69 cl, 7 tbl, 64 ex

Up!